RHEUMATOLOGY风湿病学
RHEUMATOLOGY(英文缩写 RHEUMATOLOGY),ISSN 1462-0324,eISSN 1462-0332,中文译名:风湿病学 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-27 至 2026-09-27，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 7.046 | Q1 |
| 2022 | 5.500 | Q1 |
| 2023 | 4.700 | Q1 |
| 2024 | 4.400 | Q1 |
| 2025 | 4.700 | Q1 |
RHEUMATOLOGY 最新收录文献
-
1. Increased mortality rate in patients with Takayasu arteritis is largely driven by early disease activity and damage: analysis of two cohorts.
PMID:日期:2026-09-25To evaluate mortality risk and pre-treatment predictors of mortality in Takayasu arteritis (TAK). From two cohorts, outcomes at last visit (survival/mortality) were recorded. Standardized mortality ratios (SMR) were computed (indirect standardization to population death rates from India and Turkiye). Cox proportional hazards regression was used to estimate predictors of mortality [hazard ratios (HR) with 95%CI]. The final multivariable-adjusted models included significant predictors of mortality from initial analyses based on demographic features, disease activity, damage (VDI), and clinical features or arterial involvement. Random forest (RF) and gradient boosted machines (GBM) machine learning tree models were used to understand the relative contributions of covariates in the multivariable-adjusted regression models to mortality risk. Among 529 patients with TAK [India, n = 310, Turkiye, n = 219, mean age at onset 29.12 years, 416 females], 54 deaths were recorded (29 out-of-hospital, 29/54 from cardiovascular disease, 10/54 from infections). Survival was 97.73%, 96.55%, 90.24% and 82.37% at 1, 2, 5, and 10 years, respectively. TAK was associated with increased mortality rate [SMR for India 35.88 (95%CI 24.41-50.94) and Turkiye 27.61 (95%CI 17.53-41.41)]. Higher baseline disease activity by ITAS2010 (HR 1.06), damage (HR 1.30), impaired renal function (HR 2.21), or abdominal aorta involvement (HR 2.03) significantly predicted mortality risk with good model discrimination accuracy (Harrell's C-statistic 0.772). Both RF and GBM models identified baseline activity and damage scores as major drivers of mortality. New-onset vascular events were largely driven by baseline ITAS2010. Increased mortality rate in TAK is largely driven by disease activity and early damage.
-
2. B-cell-targeted therapy for systemic lupus erythematosus-associated warm autoimmune haemolytic anaemia: a real-world comparative cohort study.
PMID:日期:2026-09-24To compare B-cell-targeted therapy with conventional glucocorticoid-based immunosuppression in first-episode systemic lupus erythematosus (SLE)-associated warm autoimmune haemolytic anaemia (AIHA). We conducted a multicampus retrospective cohort study from 1 March 2020 to 1 February 2026. Eligible patients had SLE-associated warm AIHA, baseline haemoglobin <90 g/L and laboratory evidence of haemolysis. Treatment exposure was classified within 14 days of treatment initiation: conventional therapy or B-cell-targeted therapy with rituximab, belimumab or telitacicept. The primary outcome was 6-month overall response rate (ORR; complete or partial response). Of 246 SLE hospitalisation records screened, 70 patients were included; 27 received conventional therapy and 43 received B-cell-targeted therapy. The B-cell-targeted therapy group was younger and had higher baseline SLEDAI-2K scores. Six-month ORR was 89.7% with B-cell-targeted therapy and 85.7% with conventional therapy (OR 1.45, 95% CI 0.19-9.61; P = 0.687), with corresponding complete response rates of 61.5% and 42.9%. At 1 month, prednisone-equivalent dose was lower with B-cell-targeted therapy (40.0 vs 50.0 mg/day; P = 0.023). Twelve-month ORR was 89.3% with B-cell-targeted therapy and 73.7% with conventional therapy, and relapse-free survival did not differ significantly. Within 6 months, 13 inpatient-recorded adverse-event episodes, including fatal events, were documented. In telitacicept-treated patients (n = 7), all evaluable patients achieved ORR at 1, 3 and 6 months. Six- and 12-month ORR did not differ significantly between treatment strategies. The numerically higher complete response rate, more stable 12-month response and earlier glucocorticoid reduction with B-cell-targeted therapy, together with the telitacicept findings, are exploratory and require prospective validation.
-
3. Unmet needs during the reproductive journey for women with systemic lupus erythematosus.
PMID:日期:2026-09-24In recent decades, pregnancy in patients with systemic lupus erythematosus (SLE) has ceased to be a contraindication and has become more common due to improved understanding of the disease and improved healthcare assistance. However, there are still many gaps in the reproductive health of women with lupus, ranging from limited guidance on contraception and the best time to conceive, to conflicting information about medication use during pregnancy and concerns regarding short- and long-term complications for both the woman and the child. Finally, access to care for women with lupus remains fragmented, and clinical studies in pregnant women remain limited, which restricts evidence-based medicine in this context. This article reviews the unmet needs during the reproductive journey of women with SLE, discussing ways in which healthcare professionals and administrators can improve care for this group of patients.
-
4. All-cause mortality in statin-associated immune-mediated necrotizing myopathy compared with idiopathic inflammatory myopathy.
PMID:日期:2026-09-24Statin-associated immune-mediated necrotizing myopathy (IMNM) is a distinct idiopathic inflammatory myopathy (IIM) associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) antibodies. The present study determined all-cause mortality among patients with statin-associated IMNM. In this retrospective cohort study of 142 adult patients with IIM evaluated at a tertiary academic medical center, statin-associated IMNM was defined by IMNM with recent statin exposure. IIM was defined by standard criteria. The primary outcome was all-cause mortality. Age-adjusted Cox proportional hazards models were the primary analyses with additional adjustments for age, diabetes mellitus, and hyperlipidemia with propensity score-weighted Cox models. Among 142 patients with IIM, 41 were statin-associated IMNM who were older and had shorter disease duration (p < 0.05). All-cause mortality was higher in statin-associated IMNM (31.7%, 13/41) than in IIM (23.8%, 24/101) (unadjusted HR 2.55, 95% CI 1.24-5.24; p = 0.011), with cardiopulmonary events and infections the major causes of death. In unadjusted analysis, statin-associated IMNM was associated with higher mortality (hazard ratio [HR] 2.55, 95% CI 1.24-5.24) and attenuated after age adjustment (HR 1.98, 95% CI 0.97-4.03) and was no longer statistically significant after adjustment for diabetes and hyperlipidemia (HR 1.70, 95% CI 0.71-4.08). Joint stratification by anti-HMGCR status and age (cutoff 60 years) demonstrated that older patients with statin-associated IMNM had the lowest survival among the four strata (log-rank P = 0.036). Statin-associated IMNM is associated with higher mortality than other myositis subtypes; this excess attenuates after adjustment for age and cardiometabolic comorbidity, indicating these pre-existing conditions identify a higher-risk clinical phenotype.
-
6. Predicting relapse in pediatric IgA vasculitis in the era of machine learning: an explainable hybrid ensemble model.
PMID:日期:2026-09-23This study aimed to develop an explainable hybrid ensemble machine learning (ML) model to predict relapse in pediatric IgA vasculitis (IgAV) using routine clinical and laboratory data. This retrospective cohort study included 653 children diagnosed with IgAV according to EULAR/PRINTO/PRES criteria. Demographic, clinical, laboratory data, and the Pediatric Vasculitis Activity Score (PVAS) at diagnosis were evaluated. Several tree-based ML algorithms were evaluated and combined using a soft voting strategy. The hybrid ensemble model combining Random Forest, AdaBoost, and Extra Trees was selected as the final model. SHapley Additive exPlanations (SHAP)-based explainability analysis was performed, and a nomogram was developed for individualized risk prediction. Conventional logistic regression analyses were also performed to identify independent predictors of relapse. Relapses were observed in 117 (17.9%) patients during follow-up. The hybrid ensemble model achieved the highest area under the receiver operating characteristic curve (AUC-ROC) (0.7504 ± 0.0856) with competitive area under the precision-recall curve (AUC-PR) (0.4540 ± 0.1308) and Brier score (0.1315 ± 0.0130). SHAP analysis identified older age at diagnosis, higher PVAS, female sex and abnormal urinalysis findings as the most influential predictors of relapse. On conventional regression analysis, PVAS was strongly associated with relapse. In addition, female sex, older age at diagnosis, rash involving the face, and abnormal urinalysis findings were independent predictors. Disease relapse in pediatric IgAV can be predicted using clinical and laboratory data with an explainable hybrid ensemble ML approach. The predictive model and nomogram may support risk stratification and targeted follow-up in children with IgAV.
-
7. Timing matters: diagnostic delay and major organ involvement in Behçet's syndrome.
PMID:日期:2026-09-22To assess the association between diagnostic delay and major organ involvement (MOI) in Behçet's syndrome (BS), accounting for time at risk and heterogeneity in disease trajectories. We conducted a retrospective monocentric cohort study including 173 patients with BS fulfilling ISG and/or ICBD criteria and with at least 5 years of follow-up. Patients were classified according to the presence or absence of MOI (ocular, neurological, gastrointestinal, or vascular involvement). Diagnostic delay was defined as the time from symptom onset to diagnosis. Logistic regression and sensitivity models assessed the association between diagnostic delay and cumulative MOI, accounting for age at onset, sex, and disease duration. Time-to-event analyses were performed among patients without MOI at disease onset to evaluate incident MOI during follow-up. Among 173 patients, 101 (58.4%) had at least one cumulative MOI. Timing of first MOI was available for 100 patients: 67 had MOI already present at disease onset, whereas 33 developed incident MOI during follow-up. Diagnostic delay was longer in patients with cumulative MOI than in those without MOI. In the initial logistic regression model adjusted for age at onset and sex, diagnostic delay was associated with cumulative MOI; however, this association was attenuated after accounting for disease duration. Time-to-event analysis among patients without MOI at disease onset did not show a statistically significant association between diagnostic delay and incident MOI. Diagnostic delay was associated with cumulative MOI in BS; however, this association was attenuated after accounting for disease duration and time at risk. The findings support the existence of heterogeneous disease trajectories, including early severe disease, incident MOI during follow-up, and absence of MOI over the observed period. These results should be interpreted as hypothesis-generating and require confirmation in prospective longitudinal studies.
-
8. Treat-to-target: LLDAS, DORIS remission, and flare prevention strategies.
PMID:日期:2026-09-22The goal of care in any medical condition is to optimise a person's current health status, with a view to positively impacting on their long-term outcomes. Since 2014 the concept of treat-to-target (T2T) in systemic lupus erythematosus (SLE) has been in development, enabled by a paradigm shift to focus on attainable treatment targets allowing for the development, validation, and adoption of a T2T approach. In this review, the history of this paradigm change will be reviewed, along with evidence from clinical trials that show increasing likelihood of achievement of these goals with more effective treatments and the associated benefit of reduced corticosteroid burden.
-
9. Outcomes of intensive care patients with acute small-vessel vasculitis: a 23-year single-centre experience.
PMID:日期:2026-09-22Patients with fulminant small-vessel vasculitis (SVV) may require intensive care unit (ICU) admission, where mortality is high. We describe outcomes and prognostic factors in ICU patients with ANCA-associated vasculitis (AAV) and anti-glomerular basement membrane (anti-GBM) disease over a 23-year period. Patients admitted with acute manifestations of new or flaring AAV or anti-GBM disease were identified from our hospital ICU database (1999-2022). Patients treated solely in high-dependency areas were excluded. Primary outcomes were mortality at 30 and 90 days and development of end-stage kidney disease (ESKD). A matched case-control analysis (1:4) adjusted for age, gender, APACHE II score and admission year was performed for a patient subgroup. 85 cases (82% AAV, 15% anti-GBM) were identified, 80% newly diagnosed. Median APACHE II score was 19. Ventilatory support and continuous venovenous haemodiafiltration were required in 92% and 66% of cases, respectively. 30-day and 90-day mortality rates were 15% and 26%, respectively. Among 90-day survivors, 17 (28%) developed new ESKD. Vasculitis treatments included cyclophosphamide (59%), rituximab (53% of AAV patients) and plasma exchange (71%). These treatments were associated with 90-day and long-term survival. Treatment for vasculitis post-2008 was associated with 90-day and long-term survival, which was not mirrored in ICU controls. This coincided with improvements to the vasculitis service and therapeutic strategies. This single-centre study reports ICU outcomes for patients with fulminant SVV over 23 years. 30 and 90-day ICU mortality were comparable with other reported values. Improvement in mortality was associated with changes in vasculitis treatment protocols.